1
|
Kaufman Y, Hunt KC, Hale G, McClure M, Latulippe D, Sivan M, Wilson J, Dorin R, Agroskin Y, Siwak M, Gerion D. Fouling of virus filtration membranes by monoclonal antibody feeds with low aggregate content. Biotechnol Bioeng 2023. [PMID: 37163237 DOI: 10.1002/bit.28420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/13/2023] [Accepted: 04/23/2023] [Indexed: 05/11/2023]
Abstract
Membrane fouling by monoclonal antibodies (mAbs) is one of the main challenges in virus-filtration processes. Previous publications attributed membrane fouling to the presence of mAb aggregates in the solution, which block the membrane pores. This fouling mechanism can be solved by a prefilter; however, it was shown that there are mAbs that severely foul the membranes (reduce permeability by 90% and more) even after prefiltering the aggregates, while other mAbs foul the membrane weakly (reduce permeability by ~10% and less). Unfortunately, the differences between the fouling- and the nonfouling mAbs have never been convincingly explained. To get a deeper insight on these differences, we measured the fouling of chemically modified Isoprene-Styrene-4-vinylpyridine (ISV) membranes (TeraPore Technologies) by 8 mAbs exhibiting different hydrophobicity and charge. The results show that mAb solutions with low concentration of aggregates foul ISV membranes via an adsorptive mechanism, and the adsorption is driven mainly by hydrophobic forces between the mAb and the membrane. The charge of the mAbs plays a secondary role in fouling. We want to emphasize that the conclusions pertain to ISV membranes; the insights presented in this paper can potentially be used to engineer new surface chemistries to mitigate fouling of other virus-filtration and/or ultrafiltration membranes.
Collapse
Affiliation(s)
- Yair Kaufman
- TeraPore Technologies, South San Francisco, California, USA
| | - K C Hunt
- TeraPore Technologies, South San Francisco, California, USA
| | - Gabriel Hale
- TeraPore Technologies, South San Francisco, California, USA
| | - Matthew McClure
- Department of Chemical Engineering, McMaster University, Hamilton, Ontario, Canada
| | - David Latulippe
- Department of Chemical Engineering, McMaster University, Hamilton, Ontario, Canada
| | - Madhavi Sivan
- TeraPore Technologies, South San Francisco, California, USA
| | - Jack Wilson
- TeraPore Technologies, South San Francisco, California, USA
| | - Rachel Dorin
- TeraPore Technologies, South San Francisco, California, USA
| | - Yury Agroskin
- TeraPore Technologies, South San Francisco, California, USA
| | - Marty Siwak
- TeraPore Technologies, South San Francisco, California, USA
| | - Daniele Gerion
- TeraPore Technologies, South San Francisco, California, USA
| |
Collapse
|
2
|
Bratcher PE, Hunt KC, Pickard K, Taylor-Cousar JL. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. J Cyst Fibros 2018; 18:e9-e10. [PMID: 30348612 DOI: 10.1016/j.jcf.2018.10.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 10/11/2018] [Accepted: 10/11/2018] [Indexed: 01/29/2023]
Affiliation(s)
- Preston E Bratcher
- Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO 80206, United States
| | - Kenneth C Hunt
- Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO 80206, United States
| | - Kyle Pickard
- Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO 80206, United States
| | - Jennifer L Taylor-Cousar
- Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO 80206, United States.
| |
Collapse
|